Clinical Trial

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2017-04-19; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT03125577
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions B-cell Malignancies
Enrollment 100 participants
Start Date 2025-08-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23